Antibody-based Biotherapeutics Asian Forum

Antibody-based Biotherapeutics Asian Forum

13-15 July，2016 | Shanghai China

 

Forum Overview

The Antibody and Antibody-based Therapeutics, classified as the most significant portion of biologics, have entered the center stage of drug discovery and been increasingly reflected through the major shift of focus in pipeline by pharmaceutical companies from small molecules to a broader portfolio with both biologics and chemical agents. Roughly, as of Nov.10. 2014, 47 monoclonal antibody products have been approved in US or Europe. Not only in Western countries, there have been also considerable biologics R&D, manufacturing and commercial activities in Asia. And in China, the Bio-industry has been designated as one of the seven strategic industries by the central government. Not so far away on Feb.28.2015, the China FDA has also released the country’s first biosimilar guidelines to establish the basic principles for development and technical evaluation of bio-similars, towards the adoption of a more concrete and well-defined regulatory pathway to further promote the bio-industry.

 

Upon these, through collaborating with SAPA-GP, supported by BioTaiwan, the Antibody-based Biotherapeutics Asian Forum aims to provide a premier communication platform with scientific sessions on R&D, Regulatory and Bioprocess Strategies, contributing the ‘Accessibility’ and ‘Affordability’ of those life-saving therapies in the region.

 

Program Key Discussions:

-- Challenges, Opportunities and Future Trends in the R&D of Therapeutic Antibody

-- Key Considerations to Develop a World-class Therapeutic Antibody Industry in China

-- Similar, Bio-better and Novel Therapeutic Antibody Development Strategies

-- Innovative Platform and Technology for Antibody Generation and Engineering

-- ADC, Bi/Multi-specific and Next Generation Modalities of Antibody Therapy

-- Biologics Processing and CMC Strategies

-- Current Advance in Bioprocessing

-- Cell Line and Culture Engineering

-- Purification and Viral Clearance Development

-- Quality, Analytics and Characterization Strategies

-- QbD, PAT, Single-use and HT Process Development

 

 

Please Click here for the up-to-date Guest Speakers

 

For more details about up-to-date agenda, attending and supporting opportunities, please contact:

 

Wei Zhang

Program Manager

Organizing Committee

The Antibody-based Biotherapeutics Asian Forum 2016

T: (86 21) 6034 0229

E: wzhang@deliver-consulting.com

W: www.abbforum.com